id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S10071 R36652 |
Coste (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2020 | Weight at birth <2500 g | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
1.65 [1.20;2.28] C excluded (control group) |
60/621 128/2,108 | 188 | 621 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9020 R30709 |
Coste (Levetiracetam) (Controls unexposed, NOS), 2020 | Weight at birth <2500 g | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 1.89 [1.45;2.47] C | 60/621 91,455/1,710,441 | 91,515 | 621 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9030 R30786 |
Kilic (Levetiracetam) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 | Low birth weight (< 2500 g) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
1.44 [0.33;6.26] C excluded (control group) |
2/26 48/876 | 50 | 26 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9031 R30789 |
Kilic (Levetiracetam) (Controls unexposed NOS) (Mixed indications), 2014 | Low birth weight (< 2500 g) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: No |
2.31 [0.54;9.76] C excluded (control group) |
2/26 23,503/673,844 | 23,505 | 26 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9032 R30792 |
Kilic (Levetiracetam) (Controls unexposed, sick) (Mixed indications), 2014 | Low birth weight (< 2500 g) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No Controls: epilepsy indication | 1.68 [0.40;7.16] C | 2/26 249/5,275 | 251 | 26 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8983 R30483 |
Artama (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2013 | Low birth weight (< 2500g) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
5.06 [0.91;28.06] C excluded (control group) |
2/13 6/173 | 8 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8984 R30495 |
Artama (Levetiracetam) (Controls unexposed, disease free), 2013 | Low birth weight (< 2500g) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes |
4.74 [1.01;22.18] excluded (control group) |
2/13 21,546/719,509 | 21,548 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8985 R30507 |
Artama (Levetiracetam) (Controls unexposed, sick), 2013 | Low birth weight (< 2500g) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 4.57 [0.87;24.10] | 2/13 65/1,793 | 67 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 3 studies | 1.93 [1.49;2.50] | 91,833 | 660 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Levetiracetam) (Controls unexposed, NOS; 2: Levetiracetam) (Controls unexposed, sick) (Mixed indications; 3: Levetiracetam) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 8983, 8984, 9030, 9031, 10071